New Releases from NCBI BookshelfLebrikizumab (Ebglyss): Indication: For the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg, whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Lebrikizumab can be used with or without topical corticosteroids: Reimbursement Recommendation [Internet].Lebrikizumab (Ebglyss): Indication: For the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg, whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Lebrikizumab can be used with or without topical corticosteroids: Reimbursement Recommendation [Internet].
